i-bodies and beyond with AdAlta’s Tim Oldham and The Market Bull

The Market Bull’s Ben Kosterich interviews Dr Tim Oldham, CEO and Managing Director of AdAlta (ASX: 1AD). Tim talks about the history of the company and what i-bodies are. Tim explains in depth AD-214 and the drug’s application for a range of fibrosis treatments such as lungs, liver, eyes and kidney. AdAlta is also developing the CAR-T treatment with Carina Biotech which could revolutionise cancer tumour treatment.

Click below to watch the interview.